Please login to the form below

Not currently logged in
Email:
Password:

Trajenta

This page shows the latest Trajenta news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim calls for "strong and united" Europe

Boehringer Ingelheim calls for

In particular, Eli Lilly-partnered diabetes franchise based on DPP-4 inhibitor Trajenta (linagliptin) climbed 23% to 1.1bn while sales of lung disease therapy Ofev (nintedanib) more than doubled to

Latest news

More from news
Approximately 2 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... The key points here are that Trajenta is used by just under 8, 000 practices but appears to have

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    This includes Germany-based Boehringer Ingelheim's disapproval of the generic comparator used in IQWiG's AMNOG assessment of the diabetes medicine Trajenta (linagliptin).

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    The launch of Trajenta has been positive in many markets around the world. ... reimbursement body IQWIG refusing to recommend several new drugs, including Boehringer's diabetes treatment Trajenta.

  • A new dogma in HTA assessment A new dogma in HTA assessment

    Ingelheim and Eli Lilly's Type 2 diabetes drug Trajenta (linagliptin).

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    6. Less than comparator. It is significant that last year, BI and Lilly decided not to launch their new diabetes drug Trajenta in Germany, blaming price controls. ... Out of the 10 products assessed last year, four have obtained poor innovation scores:

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics